Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Single-center, Randomized, Double-blind, Placebo- and Moxifloxacin-controlled, 4-way Crossover Phase 1 Study to Assess the Effect of Multiple Therapeutic and Supratherapeutic Doses of Aprocitentan on the QT Interval Duration in Healthy Subjects

Next Previous
Trial Profile

Prospective, Single-center, Randomized, Double-blind, Placebo- and Moxifloxacin-controlled, 4-way Crossover Phase 1 Study to Assess the Effect of Multiple Therapeutic and Supratherapeutic Doses of Aprocitentan on the QT Interval Duration in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprocitentan (Primary) ; Moxifloxacin
  • Indications Cardiovascular disorders; Hypertension; Resistant hypertension
  • Focus Adverse reactions
  • Sponsors Idorsia Pharmaceuticals

Most Recent Events

  • 27 Sep 2022 Results assessing safety of aprocitentan in healthy subjects, presented at the 2022 American College of Clinical Pharmacology Annual Meeting.
  • 07 Sep 2021 Status changed from active, no longer recruiting to completed.
  • 03 Sep 2021 Planned End Date changed from 1 Aug 2021 to 1 Sep 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top